Imeglimin and DPP-4 inhibitors: A promising therapeutic strategy for type 2 diabetes individuals with reduced insulin secretion. Hamamoto Y, Usui R. Diabetes Obes Metab 2025 Apr 21. doi: 10.1111/dom.16397.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hamamoto Y, Usui R. Imeglimin and DPP-4 inhibitors: A promising therapeutic strategy for type 2 diabetes individuals with reduced insulin secretion. Diabetes Obes Metab 2025 Apr 21. doi: 10.1111/dom.16397.
PMID: 40259492